当前位置: 首页 > 药学版 > 药品研究 > 药物与临床
编号:176401
缬沙坦与非洛地平对照治疗高血压动脉硬化性脑梗死68例
http://www.100md.com 2002年5月25日 新药网
     闵连秋,刘学文,袁静

    (锦州医学院附属第一医院神经内科, 锦州 121001)

    [摘要] 目的: 探讨缬沙坦与非洛地平对照治疗脑梗死的临床疗效和安全性。 方法: 68例脑梗死患者随机分成研究组和对照组,2组患者年龄、性别、伴发疾病和既往史积分、治疗前神经功能缺损程度评分均相似,具有可比性(P﹥0.05)。2组基础治疗相同,研究组在此基础上加用缬沙坦80mg,qd,连用4周为1个疗程;对照组应用非洛地平5mg,qd,连用4周为1个疗程。2组在治疗前后均进行神经功能缺损程度评分和疗效评定。 结果: 缬沙坦能减少脑梗死患者的神经功能缺损程度评分;治疗脑梗死有效率为88.24%,与对照组(70.59%)相比差异有显著性( P﹤0.05)。不良反应少且轻微。 结论: 缬沙坦能降低脑梗死患者的神经功能缺损程度评分,治疗脑梗死安全有效。

    [关键词] 缬沙坦;非洛地平 ; 高血压; 脑梗死; 疗效
, 百拇医药
    [中图分类号] R972.4; R969.4; R743.3 [文献标识码] A

    A Prospective, Randomized, Felodipine Controlled Trial Research on

    Valsartan for the Treatment of Cerebral Infarction

    MIN Lian-qiu1, LIU Xue-wen1, YUAN Jing1, ZHENG Chun-lan2,MA Yan-hui2, YANG Li1, ZHANG Jing-bo1, HOU Feng-ying1

    (1 Department of Neurology, The First Affiliated Hospital, Jinzhou Medical College, Jinzhou 121001, China;
, 百拇医药
    2 Department of Neurology, Fuxin Central Hospital, Fuxin 123000, China)

    [Abstract] Objective To investigate the efficacy and safety of Valsartan in the treatment of ischemic cerebral infarction. Methods 68 patients with ischemic cerebral infarction within the first 72 hours after the onset of the disease were randomly divided into study group and control group. Both groups were similarity in age, sex, concomitant disease and history of past illness scores and neurologic deficit scores before medication, and had comparability. The study group were given Valsartan 80mg,qd,po for 4 weeks. The control group received Felodipine 5mg, qd for 4 weeks. Blood and urine routine, liver and kidney function, blood lipid, free blood sugar, electrocardiograph, plasma fibrinogen levels and platelet aggregation rate were determined, neurologic deficit degree score was examined and the efficacy and safety were evaluated. Results Valsartan can reduce neurologic deficit scores of the patients with ischemic cerebral infarction(P﹤0.05). The total effective rate is 88.24% for Valsartan in the treatment of cerebral infarction, and there was significant difference than control group (P<0.05). The side-effect is light. Conclusion Valsartan is a new safe drug that has curative effect and reliable in treatment of cerebral infarction.
, 百拇医药
    [Key words] valsartan, felodipine; hypertension, ischemic cerebral infarction, curative effect

    [作者简介] 闵连秋(1963-),男,副主任,副主任医师。主要研究方向:脑血管疾病的基础与临床研究和神经药理研究。联系电话:(0416)4161868。

    [参考文献]

    [1] Fornes P, Richer C, Vacher E, et al. Losartan’s protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal(J). J Cardiovasc Pharmacol, 1993, 22(2):305-313
, 百拇医药
    [2] Lebrun CJ, Blume A, Herdegen T, et al. Angiotensin Ⅱinduces a complex activation of transcription factors in the rat brain: expression of Fos,Jun and Krox proteins(J). Neuroscience,1995,65(1):93-99

    [3] Dai WJ, Funk A, Herdegen T, et al. Blockade of central angiotensin AT1 receptors improves neurological outcome and reduces expression of AT1 transcription factors after focal brain ischemia in rats(J).Stroke, 1999, 30(11):2391-2399
, http://www.100md.com
    [4] 中华神经科学会,中华神经外科学会。各类脑血管疾病诊断要点(J)。中华神经科杂志,1996,29(6):379-380

    [5] 陈清棠。脑卒中患者临床神经功能缺损程度评分标准(1995)附件一、附件二及附件三(J)。中华神经科杂志,1996,29(6):381-382

    [6] 1993 guidelines for the management of mild Hypertension memorandum from a Word Health Organization/International Society of Hypertension Meeting(J).Hypertension,1993,22:392-403

    [7] Polidori C, Ciccocioppo R, Pompei P. Functional evidence for the ability of Angiotensin AT1 receptors antagonists to cross the blood-brain barrier in rats(J). Eur J Pharmacol, 1996,307(3):259-267
, 百拇医药
    [8] 潘启超。新抗高血压药-血管紧张素Ⅱ受体阻断剂缬沙坦的研究(J)。中国新药杂志,1999,9(8):587-590

    [9] Yu K, Lu D, Paddy MR, et al. Angiotensin Ⅱ regulation of plasminogen activator inhibitor-1 gene expression in neurons of normotensive and spontaneously hypertensive rat brain(J). Endocrinology,1996,137(6):2503-2513

    [10] Lottermose K, Weisser B, Hertfelder HJ, et al. Antihypertensive drug treatment and fibrinolytic function(J). Am J Hypertens, 1998, 11(3 Pt 1):378-384, 百拇医药